A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

被引：2

作者：

O'Donnell, Elizabeth K. ^{[1
]}

Mo, Clifton C. ^{[1
]}

Yee, Andrew J. ^{[2
]}

Nadeem, Omar ^{[1
]}

Branagan, Andrew R. ^{[3
]}

Laubach, Jacob ^{[4
]}

Rosenblatt, Jacalyn ^{[5
]}

Horick, Nora ^{[6
]}

Richardson, Paul G. ^{[7
]}

Raje, Noopur ^{[8
]}

Cirstea, Diana ^{[8
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA

[4] Harvard Med Sch, Dana Farber Partners CancerCare, Boston, MA 02115 USA

[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Dana Farber Canc Inst Inc, Boston, MA USA

[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
O'Donnell, Elizabeth K.
Mo, Clifton C.
Nadeem, Omar
Yee, Andrew J.
Branagan, Andrew R.
Laubach, Jacob
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Rosenblatt, Jacalyn
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2022, 140 : 7282 - 7283
[2] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob P.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Spillane, Kerry
LaStofka, Brenton
Rosenblatt, Jacalyn
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[3] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
O'Donnell, Elizabeth
Mo, Clifton
Yee, Andrew J.
Nadeem, Omar
Laubach, Jacob
Rosenblatt, Jacalyn
Munshi, Nikhil
Midha, Shonali
Cirstea, Diana
Chrysafi, Pavlina
Horick, Nora
Richardson, Paul G.
Raje, Noopur
LANCET HAEMATOLOGY, 2024, 11 (06): : e415 - e424
[4] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[5] A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma
Biran, Noa
Vesole, David H.
Parmar, Harsh
Phull, Pooja
Doucette, Kimberly
Feinman, Rena
Zenreich, Joshua
Anand, Palka
Ivanovski, Kristin
Pace, Monique
Biamonte, Lisa
Campanaro, Martha
McClendon, Trina
Limbad, Chandani
BaboolallAracena, Samanta
Aleman, Adolfo
Unawane, Rashmi
Pendergrass, Elizabeth
Layton, Marie
Breeze, Genevieve
Chappell, Aimee
Della Pia, Alexandra
Kumka, Susan
Siegel, David S.
BLOOD, 2023, 142
[6] A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma
Biran, Noa
Vesole, David H.
Parmar, Harsh V.
Phull, Pooja
Doucette, Kimberley
Feinman, Rena
Zenreich, Joshua
Anand, Palka
Ivanovski, Kristin
Pace, Monique
Breeze, Genevieve
Amer, Rania
Biamonte, Lisa
Aleman, Adolfo
Unawane, Rashmi
Pendergrass, Elizabeth
Della Pia, Alexandra
Kumka, Susan
Siegel, David Samuel DiCapua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Derman, Benjamin A.
Cooperrider, Jennifer
Rosenblatt, Jacalyn
Avigan, David E.
Rampurwala, Murtuza
Barnidge, David
Major, Ajay
Karrison, Theodore
Jiang, Ken
Ramsland, Aubrianna
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[8] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, Jagoda K.
Kubicki, Tadeusz
Raje, Noopur
Vij, Ravi
Reece, Donna
Berdeja, Jesus
Derman, Benjamin A.
Rosenbaum, Cara A.
Richardson, Paul
Gurbuxani, Sandeep
Major, Sarah
Wolfe, Brittany
Stefka, Andrew T.
Stephens, Leonor
Tinari, Kathryn M.
Hycner, Tyler
Rojek, Alexandra E.
Dytfeld, Dominik
Griffith, Kent A.
Zimmerman, Todd M.
Jakubowiak, Andrzej J.
BLOOD, 2020, 136 (22) : 2513 - 2523
[9] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Nievergall, Eva
Fenk, Roland
Bertsch, Uta
Tichy, Diana
Besemer, Britta
Duerig, Jan
Schroers, Roland
Metzler, Ivana V.
Haenel, Mathias
Mann, Christoph
Asemissen, Anne-Marie
Heilmeier, Bernhard
Huhn, Stefanie
Kriegsmann, Katharina
Weinhold, Niels
Luntz, Steffen P.
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Khandanpour, Cyrus
Knauf, Wolfgang
Munder, Markus
Geer, Thomas
Riesenberg, Hendrik
Thomalla, Joerg
Hoffmann, Martin
Raab, Marc-Steffen
Salwender, Hans
Weisel, Katja
BLOOD, 2021, 138
[10] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
Nishimura, Noriko
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nagata, Yasuyuki
Okaduka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215

← 1 2 3 4 5 →